Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.59 |
| ▸ | PGR | P06401 | 12/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759200 | 1.00 | NR3C1 (0.59) | NR3C1PGRNR3C2 | |
| SCHEMBL3757358 | 1.00 | NR3C1 (0.59) | NR3C1PGRNR3C2 | |
| SCHEMBL31390397 | 1.00 | NR3C1 (0.59) | NR3C1PGRNR3C2 | |
| SCHEMBL31390401 | 1.00 | NR3C1 (0.59) | NR3C1PGRNR3C2 | |
| SCHEMBL31390424 | 1.00 | NR3C1 (0.59) | NR3C1PGRNR3C2 | |
| SCHEMBL12755287 | 0.90 | NR3C1 (0.67) | NR3C1PGRNR3C2 | |
| SCHEMBL12551705 | 0.88 | NR3C1 (0.55) | NR3C1PGRNR3C2 | |
| SCHEMBL3775475 | 0.85 | NR3C1 (0.53) | NR3C1PGRNR3C2 | |
| SCHEMBL31390399 | 0.85 | NR3C1 (0.53) | NR3C1PGRNR3C2 | |
| SCHEMBL31390427 | 0.85 | NR3C1 (0.53) | NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8282909-B2 | Pharmaceutical composition for topical application of poorly soluble compounds | INTENDIS GMBH (DE) | 2012-10-09 | — | — | US | claimed |
| EP-1844039-B1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AG (DE) | 2009-07-15 | — | — | EP | claimed |
| US-7417056-B2 | 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | SCHERING AG (DE) | 2008-08-26 | — | — | US | claimed |
| EP-1844039-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | claimed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | claimed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | claimed |
| US-12496304-B2 | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing | AKRIBES BIOMEDICAL GMBH (AT) | 2025-12-16 | — | — | US | disclosed |
| EP-3914249-B1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2024-05-01 | — | — | EP | disclosed |
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2022-02-17 | — | — | US | disclosed |
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2022-02-17 | — | — | US | disclosed |
| EP-3914249-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | Akribes Biomedical GmbH (AT) | 2021-12-01 | — | — | EP | disclosed |
| CN-113382730-A | Selective glucocorticoid receptor modifiers for treatment of impaired skin wound healing | 阿克里斯生物医药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| WO-2020152193-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | AKRIBES BIOMEDICAL GMBH (AT) | 2020-07-30 | — | — | WO | disclosed |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH HEALTH US, LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | SALIX PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1844039-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006050998-A1 | 5-SUBSTITUTED QUINOLINE AND ISOQUINOLINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116396-A1 | 5-Substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents | NFKBIA, PTGS2, PTGES2 | NR3C1 2604/4885PGR 3086/4885NR3C2 1476/4885 |
| US-20220047602-A1 | SELECTIVE GLUCOCORTICOID RECEPTOR MODIFIERS FOR TREATING IMPAIRED SKIN WOUND HEALING | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 82/4885NR3C2 2/4885 |
| US-20080031884-A1 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | PTGIR, GCGR, NR3C1 | NR3C1 3/4885PGR 207/4885NR3C2 36/4885 |
| US-20080009437-A1 | Pharmaceutical Compositions and Method for Treating Dry Eye | NR3C1, GCGR, GPBAR1 | NR3C1 1/4885PGR 45/4885NR3C2 15/4885 |
| US-12496304-B2 | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 82/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.